Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome-Reference-Cited by-同舟云学术

Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome

Published:2020-01 Issue:1 Volume:156 Page:38-44
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Cecere Sabrina Chiara,Giannone Gaia,Salutari Vanda,Arenare Laura,Lorusso Domenica,Ronzino Graziana,Lauria Rossella,Cormio Gennaro,Carella Claudia,Scollo Paolo,Ghizzoni Viola,Raspagliesi Francesco,Di Napoli Marilena,Mazzoni Enrica,Marchetti Claudia,Bergamini Alice,Orditura Michele,Valabrega Giorgio,Scambia Giovanni,Maltese Giuseppa,De Matteis Elisabetta,Cardalesi Cinzia,Loizzi Vera,Boccia Serena,Naglieri Emanuele,Scandurra Giuseppa,Pignata Sandro

Funder

Associazione per la Ricerca sul Cancro

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference34 articles.

1. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†;Colombo;Ann. Oncol.,2019

2. Cancer statistics;Siegel;CA A Cancer J. Clin.,2017

3. Fifth ovarian cancer consensus conference of the gynecologic cancer InterGroup: recurrent disease;Wilson;Ann. Oncol.,2017

4. Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option;Buechel;Ann. Oncol.,2019

5. Latest clinical evidence and further development of PARP inhibitors in ovarian cancer;Mirza;Ann. Oncol.,2018

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular biology as a driver in therapeutic choices for ovarian cancer;International Journal of Gynecologic Cancer;2024-08-28

2. Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer;Frontiers in Oncology;2024-07-29

3. Real-world Study on the Effect of PARPi as Maintenance Therapy on Platinum Sensitivity after First- and Second-line Chemotherapy in Patients with Recurrent High-grade Serous Epithelial Ovarian Cancer;Current Cancer Drug Targets;2024-07

4. OPERA: a phase II trial of oregovomab plus non-platinum chemotherapy in PARP inhibitor/platinum-resistant ovarian cancer;Future Oncology;2024-06-28

5. Olaparib maintenance therapy for platinum‐sensitive relapsed ovarian cancer at a single institution: A retrospective study;Journal of Obstetrics and Gynaecology Research;2024-05-14